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Cytosolic Phospholipase A2 Plays
a Key Role in the Pathogenesis
of Multiple Sclerosis-like Disease
to macrophage influx and activation facilitated by an
increased permeability of the blood-brain barrier (Comp-
ston and Coles, 2002; Noseworthy et al., 2000; Steinman
et al., 2002; Hemmer et al., 2002; Owens and Sriram,
1995). A number of pro-inflammatory chemokines and
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cytokines such as CCL2/MCP-1, CCL3/MIP-1, CCL4/Montreal, Quebec H3G 1A4
MIP-1, CCL5/RANTES, CCL7/MCP-3, CXCL9/Mig,Canada
CXCL10/IP-10, M-CSF, TNF-, IL-1, IL-1, IL-2, IL-6,
IL-12, IFN, and GM-CSF are produced by these immune
cells and CNS glia and are expressed in the CNS in MS
and EAE (Bettelli and Nicholson, 2000; Carmody et al.,Summary
2002; Gerard and Rollins, 2001; Glabinski et al., 2003;
Godessart and Kunkel, 2001; Godiska et al., 1995; Hul-Multiple sclerosis (MS) is an inflammatory demyelinat-
kower et al., 1993; Ibrahim et al., 2001; Lock et al., 2002;ing disease of the central nervous system (CNS) that
Owens and Sriram, 1995; Rajan et al., 2000; Ransohoff,results in motor and sensory deficits. Although MS
2002). These factors initiate a pathogenic cascade inand its animal model, experimental autoimmune en-
the CNS leading to inflammation, demyelination, andcephalomyelitis (EAE), are thought to be T cell-medi-
axonal damage, which contribute to the functional def-ated diseases, the mechanisms underlying the lesions
icits.in the CNS are not fully understood. We propose that
A molecule that could serve as a central mediator ofa strong candidate as a central mediator in evoking
the pathology in MS and EAE is the enzyme phospholi-the complex pathological changes seen in MS and
pase A2 (PLA2). The expression or activation of PLA2 canEAE is the enzyme cytosolic phospholipase A2 (cPLA2).
be induced by many of the chemokines and cytokinesOne of the metabolic products of this enzyme is pro-
mentioned above such as CCL2/MCP-1, CCL3/MIP-1,inflammatory, while the other induces myelin break-
CCL5/RANTES, CCL7/MCP-3, M-CSF, TNF-, IL-1,down, demyelination, and chemokine/cytokine ex-
IL-, IFN, and GM-CSF (Murakami et al., 1997; Locatipression. We provide evidence that cPLA2 is highly
et al., 1994, 1996). It consists of a family of phospholipidexpressed in EAE lesions and show that blocking this
hydrolyzing enzymes whose metabolic products medi-enzyme leads to a remarkable reduction in the onset
ate both inflammation and demyelination (Murakami etand progression of EAE.
al., 1997; Dennis, 1994; Ousman and David, 2000). PLA2
enzymes play a normal physiological role in phospho-Introduction
lipid metabolism, host defense, and signal transduction
(Brown et al., 2003). They hydrolyze an ester bond atMultiple sclerosis is among the most common neurologi-
the sn-2 position of phospholipids that generates a freecal diseases of young adults (Compston and Coles,
fatty acid such as arachidonic acid (AA) and a lysophos-2002). It is thought to involve an autoimmune response
pholipid such as lysophosphatidylcholine (LPC) (Mura-whereby myelin-reactive T cells enter the CNS and initi-
kami et al., 1997; Dennis, 1994). Arachidonic acid canate the disease (Compston and Coles, 2002; Noseworthy
give rise to eicosanoids via cyclooxygenase (COX-1 andet al., 2000; Steinman et al., 2002; Hemmer et al., 2002).
2) and 5-lipoxygenase (5-LO) enzymes. EicosanoidsThe etiology and pathogenesis of this disease are still
such as prostaglandins, thromboxanes, and leuko-
not fully understood. Although various factors may
trienes are potent mediators of inflammation by increas-
cause MS, they appear to trigger a common mechanism
ing vascular permeability and inducing chemotaxis of
because the resulting pathology, i.e., immune cell infil- immune cells (Dennis et al., 1991). In addition, LPC is a
tration into the CNS and changes in the CNS leading myelinolytic agent and can act as a chemoattractant for
to demyelination, are similar. Identification of such a immune cells (Ousman and David, 2000; Ryborg et al.,
common mechanism would help in understanding the 1994, 2000). Injection of LPC into the spinal cord causes
pathogenesis of MS and also permit the development demyelination as well as inducing the expression of a
of more effective treatment strategies. number of chemokines and cytokines (Ousman and Da-
Experimental autoimmune encephalomyelitis (EAE) is vid, 2000, 2001). An abnormally high expression of PLA2
an inflammatory, demyelinating disease that can be in- in the CNS could therefore lead to inflammation and de-
duced by immunizing animals against myelin antigens myelination.
(Johns et al., 1995; Owens and Sriram, 1995; Slavin et PLA2 could serve as a convergence point in the induc-
al., 1998; Steinman, 1999). It has been widely used as tion of MS and EAE pathology because it can be induced
an animal model for MS as it has similarities based on by a variety of chemokines and cytokines present in the
both the histopathology and the clinical course of the CNS in the early stages of these diseases and because
affected animals (Owens and Sriram, 1995; Steinman, its metabolic products mediate both inflammation and
1999). During an attack, there is perivascular infiltration demyelination. PLA2 enzymes fall broadly into two main
of myelin-reactive T cells into the CNS, which leads groups: secreted (sPLA2) and cytosolic (cPLA2). The se-
creted form is a low molecular weight form (14 kDa) that
has no preference for the type of fatty acid at the sn-2*Correspondence: sam.david@mcgill.ca
Neuron
324
Figure 1. cPLA2 Is Expressed in EAE Lesions
(A) Representative sections of lumbar spinal
cord of mice with EAE at clinical grades 1–4
from the first paralytic episode are shown.
cPLA2 endothelial cells are seen in grades
1–3 indicated by arrowheads. Endothelial
cells that do not express cPLA2 are seen in
grade 4. cPLA2 immune cell clusters in peri-
vascular locations are seen at all clinical
grades, indicated by arrows. Scale bars equal
30 m.
(B) Changes in the percentage of cPLA2 en-
dothelial cells in all EAE lesions in cross-sec-
tions of the lumbar spinal cord. High percent-
age of endothelial cells express cPLA2 during
the earlier stages of the first attack (grades
1 to 3) and was reduced at grades 4 and 5
(*grade 1 versus 4 and 5, p  0.003; **grade
2 versus 4 and 5, p  0.01; ***grade 3 versus
4 and 5, p  0.01).
(C) Changes in the total number of immune
cells in all EAE lesions in cross-sections of
the lumbar spinal cord. The number of im-
mune cells in EAE lesions increases at later
clinical grades of 4 and 5 (*grade 1 versus 4
and 5, p  0.0005; **grade 2 versus 4 and 5,
p  0.004; ***grade 3 versus 4, p  0.02).
(D) Changes in the number of cPLA2 immune
cells in all EAE lesions in cross-sections of the
lumbar spinal cord. The number of cPLA2
immune cells in EAE lesions of the first para-
lytic episode also increases at later clinical
grades (*grade 1 versus 3, 4, and 5, p  0.04,
0.02, 0.001, respectively; **grade 2 versus 3,
4, and 5, p  0.01).
position of phospholipids (Murakami et al., 1997; Dennis, 30%–50% in various clinical grades at all levels of the
spinal cord. However, since the total number of immune1994). Members of the cytosolic form have a higher
molecular mass (85–110 kDa) and selectively hydrolyze cells in the infiltrates increases with increasing clinical
grade (Figure 1C), the total number of immune cellsphospholipids containing AA (Murakami et al., 1997;
Dennis, 1994). Certain mouse strains, such as C57BL/6, expressing cPLA2 also increases with increasing sever-
ity of the disease (Figure 1C). The high cPLA2 expression129/Sv, and B10.rIII, have a naturally occurring null mu-
tation of the major form of sPLA2 (Kennedy et al., 1995). seen in endothelial cells at the early clinical grades (Fig-
ure 1C) precedes the largest increase in immune cellWe therefore assessed the expression of cPLA2 in EAE
lesions and the effects of inhibiting this enzyme on the entry into the CNS seen at more severe clinical grades
(Figure 1C). Furthermore, mice that had reached a gradeonset and progression of EAE in C57BL/6 mice.
3 and remitted to a grade 1 did not have any cPLA2
immune cells or endothelial cells in the spinal cord (dataResults
not shown).
Double-immunofluorescence labeling indicates thatcPLA2 Is Expressed in EAE Lesions
We first assessed the expression of cPLA2 in the spinal both CD4 T cells and Mac-1 macrophages express
cPLA2 in these immune cell infiltrates (Figures 2B andcord of C57BL/6 mice with EAE. If PLA2 plays a role in
MOG-induced EAE in C57BL/6 mice, it has to be medi- 2C). The number of CD4 T cells expressing cPLA2 in
lesions remains the same throughout the different clini-ated mainly by cPLA2, because this strain lacks the ma-
jor form of sPLA2. Increased expression of cPLA2 was cal grades (Figure 2C), whereas the number of macro-
phages expressing cPLA2 in EAE lesions increases withobserved by immunohistochemistry at the site of EAE
lesions. This increased expression was assessed in cer- disease severity (Figure 2). Collectively, these data indi-
cate that cPLA2 is expressed in the CNS very early duringvical, thoracic, and lumbar regions of the spinal cord of
mice at clinical grades of 1–5 during their first paralytic the clinical course of EAE, may contribute to the influx
of inflammatory cells into the CNS, and may underlie theattack. The immunohistochemical labeling for cPLA2 oc-
curred in both endothelial cells and immune cells in the pathological and clinical changes characteristic of EAE.
CNS inflammatory infiltrates (Figure 1A). A high percent-
age of cPLA2 endothelial cells were seen in the spinal Blocking cPLA2 Prevents Onset
and Progression of EAEcord early in the course of the disease, ranging from
about 60%–85% in grades 1–3 and decreased to about To assess if cPLA2 is important for the onset of EAE, we
blocked it using an AA analog, arachidonyl trifluromethyl20% at clinical grades 4 and 5 (Figure 1B). The percent-
age of cPLA2 immune cells in EAE lesions remained at ketone (AACOCF3), which is a potent and selective inhib-
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of the disease was also markedly reduced in the treated
mice. Control animals reached an average maximum
clinical score of about 3 at day 15, while the 2 mM and
4 mM treated groups reached scores of 1.3 and 0.4,
respectively (Figure 3). When only the animals that got
EAE symptoms in the 2 mM and 4 mM treated groups
were considered, they reached a mean maximal grade
of 2.25 and 1.5, respectively, on day 15, compared to
a 2.9 seen in the control group (Table 1), indicating
that the small percentage of mice treated with 4 mM
AACOCF3 that got EAE showed a remarkably milder form
of the disease. Unlike the controls, which relapsed into
a second paralytic episode between days 25 and 34,
mice treated with 4 mM AACOCF3 remained largely unaf-
fected (Figure 3, Table 1). The treatment is well tolerated
in that the animals did not show any observable side
effects. These data suggest that the inhibitor treatment
is well tolerated and can prevent disease when given
before symptoms occur.
To examine the effects of the inhibitor treatment at
the protein level, we first assessed the expression of
cPLA2 and one of the downstream enzymes, COX-2, in
the spinal cords of untreated EAE mice that reached a
clinical score of grade 3 on day 13; mice treated with
AACOCF3 that were also sacrificed on day 13 in which
the disease was prevented; and normal healthy control
mice. Cytosolic PLA2, seen as an 85 kDa band on West-
ern blots, was elevated in untreated EAE mice as com-
pared to normal controls (Figure 4A). COX-2, a 72 kDa
Figure 2. Immune Cell Types Expressing cPLA2 enzyme downstream of cPLA2 that is responsible for the
production of prostaglandins and thromboxanes, was(A) Double-immunofluorescence micrographs showing CD4 T cells
(red, left) expressing cPLA2 (green, middle) and the double labeled also elevated in untreated mice with EAE as compared
cells (yellow, right) in EAE lesions. to normal controls (Figure 4A). In contrast to untreated
(B) Mac-1macrophages (red, left) expressing cPLA2 (green, middle) mice with EAE, both cPLA2 and COX-2 are present atand double labeled cells (yellow, right) in EAE lesions in the lumbar
much reduced levels in AACOCF3-treated EAE mice (Fig-spinal cord. Scale bar equals 100 m.
ure 4A). These results were consistently seen in three(C) Graph showing changes in the mean number of CD4 T cells in
separate experiments.five randomly selected EAE lesions. There were a similar number of
CD4 T cells expressing cPLA2 in the infiltrates at all clinical grades. To further assess the effects of cPLA2 inhibitor treat-
(D) Graph showing changes in the number of cPLA2 macrophages ment on gene expression in the spinal cord of EAE mice,
in five randomly selected EAE lesions. The number of cPLA2macro- we carried out a gene array analysis of 67 genes for
phages in these lesions increased progressively from grade 1 to chemokines and their receptors and 96 cytokine genes
grade 5 (*grade 1 versus 3, 4, and 5, p 0.03, 0.03, 0.01, respectively;
using arrays from Superarray Bioscience Corp (Freder-**grade 2 versus 5, p  0.03; ***grade 3 versus 5, p  0.01).
ick, MD). This analysis was carried out on spinal cords
of untreated EAE mice with a clinical score of grade 3
on day 13, mice from the inhibitor treated group also
itor of cPLA2 (Street et al., 1993). This inhibitor shows sacrificed on day 13 in which the disease was prevented,
slow tight binding to cPLA2 in the presence of Ca2 and and normal healthy control mice (Figure 4B). Ten of
forms a covalent bond with a serine residue in the active the cytokine genes and 26 of the chemokines and their
site of the enzyme (Street et al., 1993; Trimble et al., receptors were increased 2-fold in mice in the un-
1993). It is about 500-fold more potent at inhibiting treated EAE group as compared to normal controls (Ta-
cPLA2 than sPLA2 (Street et al., 1993). It may also be a bles 2 and 3). In the cPLA2 inhibitor-treated mice, the
weak inhibitor of the calcium-independent form of PLA2 expression of 80% of these genes returned to normal
(Riendeau et al., 1994; Ackermann et al., 1995; Gho- levels, while 14% were reduced but still remained higher
mashchi et al., 1999). Arachidonyl analogs have been than in normal controls (these include CCR5, CXCR4,
shown to be relatively nontoxic to cells (Riendeau et al., CCL19/MIP-3, Dfy, and angiopoietin 2), and 6% were
1994). C57BL/6 mice were treated with AACOCF3 on the similar to the EAE levels (CXCL12/SDF-1 and CX3CL1/
day of induction of EAE and on day 2 with 50 l of 2 or fractalkine) (Figures 4C and 4D). Many of the chemokine/
4 mM AACOCF3 intravenously, followed by intraperito- chemokine receptor and cytokine genes that were ele-
neal injections of the inhibitor (200 l at 2 or 4 mM) on vated in untreated EAE mice are those that have already
alternate days until day 24. Treatment with the inhibitor been implicated in the pathogenesis of EAE (Table 2).
resulted in a remarkable reduction in the onset and pro- Interestingly, several genes not previously implicated in
gression of EAE. 100% of the control mice got EAE, EAE (Table 3) increased in expression substantially in
while 57% of the 2 mM treated and only 28% of the 4 EAE mice. Some of these have or are likely to have
biological effects on immune cells and so are possiblemM treated groups got EAE (Table 1). The progression
Neuron
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Table 1. Clinical Characteristics of Mice Induced with EAE and Treated with the cPLA2 Inhibitor AACOCF3
Mean Clinical Mean Clinical
Mean Clinical Grade of Only Mean Clinical Grade of Only
Mean Day Grade of All Animals with Grade of All Animals with
of Disease Animals at Disease at % Relapse Animals at Disease at
n % Incidence Onset Day 15 Day 15 by Day 26 Day 60 Day 60
Untreated control 9 100% (9/9) 9.6  0.6 2.9  0.2 2.9  0.2 88.9% (8/9) 1.8  0.2 1.8  0.2
Treated: 2 mM AACOCF3 14 57% (7/14) 10.3  0.3 1.3  0.3 2.3  0.4 21.4% (3/14) 1.1  0.2 1.6  0.2
p value 0.01 NS 0.001 NS 0.004 0.03 NS
Treated: 4 mM AACOCF3 14 28% (4/14) 10.7  1.0 0.4  0.30 1.5  0.6 7.1% (1/14) 0.2  0.1 0.8  0.3
p value 0.003 NS 0.0001 0.01 0.001 0.0001 0.005
Animals were given treatment at the time of EAE induction until day 24. Data represent mean  SEM. p values compared with untreated
control. NS, not significant.
new candidates in EAE pathology (Table 3). Others are mation such as COX-2, LTB4R2, and pro-inflammatory
chemokines and cytokines, many of which (namelynot known to have their primary effects on the immune
CCL3/MIP-1, CCL7/MCP-3, M-CSF, IL-1, IL-1, andsystem, and their role in EAE remains to be determined.
IFN-) are known to induce the expression of cPLA2The gene for fibroblast growth factor-12 (FGF-12) was
(Locati et al., 1994, 1996; Murakami et al., 1997) or tohighly expressed in normal controls and was reduced
be induced by its metabolic product, LPC (Ousman andto 0.5-fold in both untreated and treated EAE groups.
David, 2001).A few other genes that may have anti-inflammatory roles
(CXCR1, IFN [gene6, gene7, and gene B], erythropoie-
Therapeutic Effect of Blocking cPLA2 in EAEtin, pleiotrophin, TGF2, and TGF3) (Agnello et al.,
To assess if blocking cPLA2 is also effective in improving2002; Racke et al., 1993; Subramanian et al., 2003; Liu
symptoms of EAE after the disease is well established,et al., 1998) were also downregulated in the untreated
C57BL/6 mice that were induced with EAE were givenEAE mice and their levels remained lower than normal
a delayed treatment with 4 mM of AACOCF3. All animalsin the inhibitor-treated mice. Of particular interest is the
reached a score of grade 3 or above by day 13. Treat-elevation of LTB4R2, the receptor for LTB4, a metabolic
ments for all mice were begun on day 14, when remis-product of cPLA2. The differences in expression of a
sions were first seen. Four 50 l intravenous injectionsselect number of chemokine and cytokine genes (CCL3/
of the inhibitor were given during a 1 week period. TheMIP-1, CXCL9/Mig, CXCL10/IP-10, IFN-, and M-CSF)
animals were divided into two groups based on whetherthat was detected with the gene array screen was further
they had a clinical score of grade 3 or above or a scoreconfirmed by RT-PCR (Figure 4E). Taken together, these
of grade of 2 or below on the first day of treatment.findings suggest that inhibiting cPLA2 in mice with EAE
Both treated groups showed a similar clinical course asleads to a decrease in many of the mediators of inflam-
compared to their respective untreated controls during
the 1 week treatment period (Figures 5A and 5B). The
group that remitted to a clinical score of 2 or below on
the first day of treatment showed a remarkable reduction
in the progression of the disease (Figure 5A). Although
these animals had initially peaked to a mean clinical
score of grade 3 prior to treatment, they progressively
dropped down to a mean grade of 0.3 and remained
virtually symptom-free up to day 60 (Figure 5A, Table
4), the maximum period studied. Their progression into
a second relapse was prevented. In contrast, their
matching untreated controls, which also remitted to a
clinical score of grade 2 or below on day 14 and which
had initially peaked to a mean grade of 3.2, progressed
into a second paralytic episode (grade 2.9) between
days 25 and 37. These mice, which display a relapsing-
remitting form of the disease, remained thereafter at aFigure 3. cPLA2 Inhibitor Prevents Onset and Progression of EAE
mean clinical score of 1.8 until day 60 (Figure 5A, TableGraph showing the clinical course of mice induced with EAE that
4). On the other hand, animals that had a clinical scorewere treated with two doses of cPLA2 inhibitor (closed circle, 2 mM
of grade 3 or above on the first day of treatment showedAACOCF3; closed square, 4 mM AACOCF3) from day 0 to 24 com-
pared to an untreated EAE control (closed down triangle). Data a chronic form of the disease and were unaffected by
represent means  SEM from two independent experiments, with the treatment regimen, not differing from the control
a total of 14 mice in each of the treated groups and 9 mice for the group (Figure 5B). These groups reached a peak mean
control group. The difference between 2 mM AACOCF3 and control clinical score of 3.4 (Figure 5B).
groups is significant during the first paralytic episode (days 12 to
Although the mice that displayed a chronic course22; p  0.001), the second paralytic episode (days 29 to 37; p 
did not show clinical improvement with the inhibitor0.01), and later periods (days 48 to 60; p  0.03). The difference
treatment, we assessed whether the treatment had anybetween 4 mM AACOCF3 and control groups is significant from day
9 to 60, p  0.0001. effect on inflammation in the spinal cord. Immune cell
cPLA2 in Experimental Autoimmune Encephalomyelitis
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Figure 4. Changes in Gene and Protein Expression in cPLA2 Inhibitor-Treated Mice
(A) Western blot of spinal cord tissue showing expression of cPLA2 in the upper panel as indicated by an 85 kDa band and COX-2 in the
lower panel as indicated by a 72 kDa band. There is high expression of both enzymes in the untreated EAE mice. Both enzymes were markedly
lower in the AACOCF3-treated mice. The enzymes were present at low levels in the normal control.
(B) Representative chemokine/chemokine receptor gene arrays showing expression in the spinal cords of untreated and treated EAE mice
taken at day 13 and a normal control mouse. Expression of many genes are increased in the untreated EAE spinal cord. The number of genes
expressed is reduced in the inhibitor-treated EAE mouse. A few genes are expressed at basal levels in the normal animal. The last 10 genes
in the bottom two rows are housekeeping genes.
(C and D) Graphs showing the normalized level of expression for the chemokine/chemokine receptor genes and cytokine genes, respectively.
The black bars indicate expression in untreated EAE spinal cord, the gray bars indicate expression in inhibitor-treated spinal cord, and the
white bars indicate expression in normal control spinal cord.
(E) RT-PCR for several chemokines and cytokines in the same groups of mice as described above. There is high expression of these genes
in the untreated EAE spinal cord, which is greatly reduced in spinal cord of AACOCF3-treated mice, and low level or no expression in normal
spinal cord.
infiltration into the spinal cord was estimated by cell 6C). Similar results were also seen in the cervical and
thoracic regions (data not shown). Furthermore, therecounts on hematoxylin and eosin (H&E) stained tissue
sections of the spinal cord obtained at day 60 (n 	 3 in was a marked reduction in the lesion burden and im-
mune cell infiltration in the other treated group, whicheach group). The untreated chronic control group (grade
2.9 on day 60) had an average of about 460 immune had remitted to a grade of 2 or less and which responded
well to inhibitor treatment (Figures 6A–6C). These resultscells in the lumbar spinal cord, with about six lesions
per section, and a lesion area of about 0.39 mm2 (Figures show that blocking cPLA2 reduces inflammation in mice
with EAE.6A–6C). In contrast, the treated chronic group that did
not show clinical improvement (grade 2.8 on day 60) Although cPLA2 inhibitor treatment was able to par-
tially block inflammation in the chronic group, this reduc-showed a reduced inflammatory burden. These treated
mice had only about 250 immune cells in EAE lesions tion in inflammation did not lead to an improvement in
the clinical score, suggesting that other factors play ain the lumbar spinal cord, with an average of four lesions
per section, and a lesion area of 0.28 mm2 (Figures 6A– role. We therefore examined Epon embedded sections
Neuron
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Table 2. Genes that Increased in Expression in Untreated EAE Mice and Have Previously Been Implicated in EAE
Fold Change
Treated/Untreated
Gene EAE Effects on Reference
Chemokine Receptors
CCR2 0.02 MCP-1/3/5 receptor Jiang et al., 1998
CCR5 0.11 MIP-1/RANTES receptor Jiang et al., 1998
CXCR2 
0.15 IL-8 receptor Glabinski et al., 2000
CXCR4 0.36 SDF-1 receptor Glabinski et al., 2000
CX3CR1 0.17 fraktalkine receptor Jiang et al., 1998
Chemokines
CCL3/MIP-1 
0.11 macrophages, granulocytes Rajan et al., 2000
CCL4/MIP-1 
0.25 macrophages, granulocytes Rajan et al., 2000
CCL6/C10 
0.95 recruitment of macrophages Asensio et al., 1999
CCL7/MCP-3 
0.13 recruitment of monocytes Godiska et al., 1995
CCL9/MIP-1 
0.38 recruitment of CD4 T cells Carmody et al., 2002
CCL11/eotaxin 
1.6 recruitment of eosinophil Rajan et al., 2000
CCL12/MCP-5 
0.18 peripheral blood monocytes Teuscher et al., 1999
CCL19/MIP-3 0.4 T cells and B cells Alt et al., 2002
CXCL1/MIP-2 
0.47 neutrophilic granulocytes Rajan et al., 2000
CXCL9/Mig 
0.08 recruitment of stimulated T cells Rajan et al., 2000
CXCL10/IP-10 
0.05 recruitment of activated T cells Rajan et al., 2000
CXCL12/SDF-1 0.94 lymphocytes and monocytes Godiska et al., 1995
CX3CL1/fractalkine 1.08 recruitment of T cells and monocytes Fischer et al., 2000
Cytokines
M-CSF 0.2 growth survival/differentiation of monocytes Hulkower et al., 1993
IFN- 
0.6 activates mononuclear phagocytes Bettelli and Nicholson, 2000
IL-1 
0.03 both IL-1 and IL-1 enhance expression of Carmody et al., 2002
adhesion molecules and facilitate CD4
T cell proliferation
IL-1 
0.04
TGF- 0.06 inhibits pro-inflammatory cytokines and pro- Bettelli and Nicholson, 2000
liferation of lymphocytes; role in regulation/
entering remission
Genes presented are those in the untreated EAE mouse spinal cord with values 2-fold as compared to normal control mouse spinal cord.
Data represents fold change of treated EAE as compared to untreated EAE spinal cord. A value of 0.5 indicates expression was reduced in
half. Those 0.5 indicates a significant reduction of expression in the treated group. A value of 1 indicates the expression is the same in both
groups. Abbreviations: MIP, macrophage inflammatory protein; MCP, monocyte chemotactic protein; Mig, monokine induced by gamma
interferon; IP, interferon inducible protein; SDF, stromal cell derived factor; M-CSF, macrophage colony stimulating factor; IFN, interferon;
TGF, transforming growth factor.
of the spinal cord by electron microscopy to assess cells and immune cells at sites of EAE lesions in the
whether there was axonal damage. Treated animals that spinal cord. This increased expression in endothelial
followed a chronic clinical course and their untreated cells during the early clinical stages of the disease may
controls both showed a great deal of axonal damage in play an important role in recruiting immune cells into
areas near EAE lesions (Figures 6D–6H). This axonal the CNS. The expression of cPLA2 in T cells and macro-
loss may account for the permanent clinical deficits seen phages could play a role in recruitment of additional
in these groups. In contrast to these chronic groups, immune cells, leading to further progression of the dis-
the control group with the relapsing-remitting course ease at later stages. We also demonstrate that by
(mean clinical score of 1.8 on day 60) showed fewer blocking the activity of cPLA2 using a chemical inhibitor
damaged axons, while the companion treated group, of this enzyme, the disease incidence can be drastically
which improved with treatment (mean clinical score of curtailed and the disease severity markedly reduced
0.3 on day 60), showed virtually no damaged axons (data when treatment is initiated at the time of induction of
not shown). These data indicate that the failure of mice EAE. This reduction in disease severity correlates with
with the more severe form of EAE to improve with the a decrease in cPLA2 and its downstream mediators such
inhibitor treatment may be due to permanent axonal as COX-2, LTB4R2, and various chemokines and cyto-
damage. kines that contribute to the inflammatory and neural
pathology in EAE. Furthermore, we show that inhibiting
cPLA2 after the disease is full-blown has a remarkableDiscussion
effect in reducing inflammation, axonal damage, and
the clinical severity and preventing further remissionsOur data indicate an important role for cPLA2 in the
in animals showing a relapsing-remitting form of thepathogenesis of EAE, the animal model of MS. We dem-
onstrate an increased expression of cPLA2 in endothelial disease.
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Table 3. Genes that Increased in Expression in Untreated EAE Mice and Have Not Formerly Been Reported in EAE
Fold Change
Gene Treated/Untreated EAE Effects on Reference
LTB4R2 0.10 receptor for a downstream metabolite of Yokomizo et al., 2000
cPLA2, which is a potent activator of
macrophages
Dfy 0.45 expressed in MS tissue, enhances leukocyte Whitney et al., 1999; Lee et al., 2003
recruitment
TAPbp/tapasin 
0.57 a member of the MHC class I loading complex Garbi et al., 2003
angiopoietin 2 0.43 blood brain barrier breakdown Nourhaghighi et al., 2003
IB 0.21 inhibitor for NF-B Murphy et al., 2002
CCL16 
0.03 chemotactic for CD4 T-lymphocytes Nomiyama et al., 2001
PUMA- 
0.12 nicotinic acid receptor Tunaru et al., 2003
FGF-9 0.44 potent mitogen for glial cells Naruo et al., 1993
FGF-17 0.12 NA
IFN gene 11 0.47 NA
CMKOR1 0.04 NA
SDF-2 
0.91 NA
Genes presented are those in the untreated EAE spinal cord with values 2-fold as compared to normal control mouse spinal cord. These
genes have not previously been implicated in EAE. Data represents fold change of treated EAE mice as compared to untreated EAE mice. A
value 0.5 indicates a reduction of expression in the treated group. Abbreviations: LTB4R2, Leukotrine B4 receptor 2; Dfy, duffy glycoprotein;
TAPbp, T cell activating protein binding protein; FGF, fibroblast growth factor; CMKOR, chemokine orphan receptor; PUMA-, protein upregu-
lated in macrophages by IFN-; NA, not yet associated with immune cells.
One of the major pathologies in MS and EAE is a after onset of EAE as compared to COX inhibitor treat-
ment (Traugott and Raine, 1989; Weber et al., 1991)complex inflammatory cascade in the CNS (Compston
and Coles, 2002; Noseworthy et al., 2000; Steinman et suggests that the effects of AACOCF3 are likely to reflect
its ability to block cPLA2.al., 2002; Hemmer et al., 2002; Owens and Sriram, 1995).
PLA2 may mediate these responses via the release of Another way cPLA2 can stimulate immune responses
is through LPC, which is a chemoattractant for T cellsAA and LPC. One way this enzyme can play a role in
inflammation is through the AA pathway, which is the and monocytes and activates macrophages (Ousman
and David, 2000, 2001; Ryborg et al., 1994, 2000). LPCprecursor of pro-inflammatory eicosanoids. The princi-
pal pathways of AA metabolism are the 5-LO pathway, also induces expression of the cell adhesion molecules
ICAM-1 and VCAM-1 by CNS endothelial cells and rap-which produces a collection of leukotrienes (LT), and the
COX pathway, which produces prostaglandin H2 (PGH2). idly opens the blood-brain barrier (Ousman and David,
2000). Importantly, LPC also induces expression of aPGH2 serves as the substrate for two enzymatic path-
ways: one leading to the production of several prosta- number of pro-inflammatory cytokines (Ousman and Da-
vid, 2001), which can further upregulate cPLA2 expres-glandins (PG), and the other leading to the production
of thromboxanes (TX) (Rocha et al., 2003). These metab- sion in a positive feedback loop (Murakami et al., 1997).
LPC can be further metabolized into platelet-activatingolites are collectively referred to as eicosanoids and
function by binding to specific cell surface receptors. factor (PAF), which is also a strong mediator of inflam-
matory processes (Murakami et al., 1997; Dennis et al.,PGE2, for example, is a potent vasodilator (James et al.,
2001; Rocha et al., 2003). TXA2 promotes lymphocyte 1991). Therefore, cPLA2 can set off a robust inflamma-
tory response in the CNS in EAE via multiple pathways.proliferation and adhesion and enhances macrophage
function (James et al., 2001; Rocha et al., 2003). It also There is evidence that the inflammatory response in
EAE can be reduced by blocking a number of chemo-facilitates the synthesis of TNF and IL-1 (Caughey et
al., 1997). LTB4 promotes leukocyte adhesion to endo- kines and cytokines (i.e., CCL3/MIP-1, CCL2/MCP-1,
TNF-, M-CSF, IL-1, IFN, and GM-CSF) (Karpus et al.,thelial cells and extravasation into tissues (Rocha et al.,
2003). It also promotes the production of pro-inflamma- 1995; Ruddle et al., 1990; Selmaj et al., 1998; McQualter
et al., 2001) that are known to induce expression oftory cytokines such as IL-1, IL-2, and IFN- by mono-
cytes and macrophages (Rocha et al., 2003; Tager and PLA2. The inflammatory response in EAE can also be
reduced by blocking cell adhesion molecules, such asLuster, 2003). Its receptor LTB4R2 is highly expressed
on CD4 and CD8 T cells (Rocha et al., 2003). These ICAM-1, which is induced by LPC (Kawai et al., 1996),
or by directly blocking prostaglandins, a metabolic prod-lipid mediators can therefore contribute to inflammation
by chemotaxis or activation of immune cells and by uct of the AA pathway (Reder et al., 1994). Depleting
macrophages, which are known to be chemoattractedincreasing vascular permeability. The generation of ara-
chidonic acid by cPLA2 is the rate-limiting step in the and activated by LTB4 and LPC, also reduce these in-
flammatory responses (Tran et al., 1998). These studiesproduction of these eicosanoids. Although AACOCF3 is
a potent inhibitor of cPLA2, there is indirect evidence provide strong support for the possibility that increased
PLA2 expression may trigger the onset and progressionthat in platelets it also has COX inhibitor activity under
conditions when exogenous arachidonic acid is added of this inflammatory and demyelinating disease.
The second major pathological feature of MS is demy-to the cells (Riendeau et al., 1994). The positive outcome
we have observed with AACOCF3 treatment delivered elination and axonal damage (Bjartmar and Trapp, 2001;
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plement activation (Selmaj and Raine, 1988; Genain et
al., 1999; Mead et al., 2002). Once the axons are demye-
linated, they can become damaged through the actions
of certain cytokines, proteolytic enzymes, and nitric ox-
ide (NO) (Bjartmar and Trapp, 2001; Smith et al., 1999).
cPLA2 can also contribute to this pathology via its meta-
bolic product LPC. Not only does LPC act as a myelino-
lytic agent itself, but in late stages of demyelination it
may also damage axonal membranes. PLA2 can also
recruit macrophages (Murakami et al., 1997), which pro-
duce NO, as well as cytokines that could result in free
radical and cytokine-mediated cytotoxicity (Noseworthy
et al., 2000; Bjartmar and Trapp, 2001). PLA2 may also
be involved at least in part in glutamate-induced toxicity
that leads to axonal and oligodendroglial damage as
glutamate release has been shown to be reduced by
PLA2 inhibitors (Sundstrom and Mo, 2002). Additionally,
two groups have generated mice lacking cPLA2 (Bon-
ventre et al., 1997; Uozumi et al., 1997), one of which
showed that cPLA2 mediates neural damage in isch-
emia-reperfusion injury as indicated by the reduced in-
farct size following transient middle cerebral artery oc-
clusion (Bonventre et al., 1997). Induction of EAE in
cPLA2 null mutants on an EAE-susceptible background
strain would help to further assess the role of cPLA2.
Additional confirmation of the importance of cPLA2 in
macrophage recruitment, myelin breakdown, and phago-
cytosis comes from our recent studies on Wallerian de-
Figure 5. Therapeutic Effect of cPLA2 Inhibitor in EAE generation in peripheral nerves (De et al., 2003).
(A) Graph showing the clinical course of mice induced with EAE that A number of approaches have been tested to amelio-
were treated with 4 injections of 4 mM AACOCF3 (closed square; n	 rate the clinical course of EAE through a variety of im-
6) between days 14 and 20 (indicated by arrows) and the untreated
munomodulatory approaches and methods to achievecontrol groups (closed triangle; n 	 9). Treated mice that recovered
protection from oligodendrocyte and axonal damageto a grade 2 or below on day 14, the first day of treatment, show a
remarkable recovery and remain almost symptom free until day 60. (Karpus et al., 1995; Ruddle et al., 1990; Selmaj et al.,
In contrast, untreated control mice that also recovered to a grade 1998; McQualter et al., 2001; Kawai et al., 1996; Reder
2 or below on day 14 show a relapsing-remitting clinical course. et al., 1994; Tran et al., 1998; Lock et al., 2002; Chabas
Differences between these groups are statistically significant from et al., 2001; Fife et al., 2001; Leger et al., 1997; Pitt et
day 28 to 60 (p  0.005).
al., 2000; Butzkueven et al., 2002; Popovic et al., 2002;(B) Graph showing the clinical course of mice induced with EAE that
Brundula et al., 2002). Of these efforts to develop newremained at a grade 3 or above on day 14, the first day of treatment
(closed circle; n 	 7), as well as the untreated control mice (closed treatments for MS, only a few have been approved for
down triangle; n 	 8) that also remained at a grade 3 or above, human use, with limited success (Polman and Uitde-
show a chronic clinical course and no improvement with inhibitor haag, 2000; Rolak, 2001). Therapies currently being used
treatment. Data represent means  SEM from two independent ex- or in various stages of clinical testing consist of
periments.
immunomodulatory drugs (Steinman, 1999; Polman and
Uitdehaag, 2000; Rolak, 2001). An optimal treatment
Trapp et al., 1998; Wujek et al., 2002). The exact mecha- would aim at preventing both inflammation and axonal
nism for demyelination and axonal injury in MS lesions damage including demyelination. This study shows that
is not known. One possible mechanism is through the cPLA2 may play a role in contributing to both the inflam-
destruction of oligodendrocytes, which can occur through matory and axonal pathologies seen in EAE. An elevated
level of PLA2 was detected in MS tissue in one studyantibody, or cytokine-mediated cytotoxicity, and com-
Table 4. Clinical Characteristics of Mice that Remitted to a Grade 2 or below on Day 14 Given a Delayed Treatment with the cPLA2 Inhibi-
tor AACOCF3
Mean Clinical Grade Mean Clinical Grade
Mean Day of of Animals at 1st of Animals at 2nd
Disease Paralytic Attack % Relapse Paralytic Attack Mean Clinical Grade
n Onset (Day 13) by Day 25 (Day 31) of Animals at Day 60
Untreated RR control 6 7.8  0.6 3.2  0.2 100% (6/6) 2.9  0.4 1.8  0.3
Treated: 4 mM AACOCF3 6 7.7  0.6 3.0  0.2 16.7% (1/6) 0.3  0.2 0.3  0.2
p value NS NS 0.05 0.0001 0.005
Animals had a score of 2 or below on the first day of treatment. Treatment given between days 14 and 20. Data represent mean  SEM. p
values compared with untreated, relapsing-remitting (RR) control. NS, not significant.
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Figure 6. Inflammation and Axonal Damage
(A) Quantitative analysis of H&E stained sec-
tions of the lumbar spinal cord revealed a
significant reduction in the number of immune
cells entering the spinal cord in both groups
of treated mice compared to their untreated
controls, *p  0.02; **p  0.03. Black bars
indicate untreated control mice with chronic
clinical course that remained at a score of 3 or
above on day 14; gray bars indicate inhibitor-
treated mice that showed a chronic course
that also remained at a score of 3 or above
on day 14; hatched bars indicate untreated
control mice that show a relapsing-remitting
clinical course that had remitted to a score of
2 or below on day 14; and white bars indicate
inhibitor-treated mice that recovered to a
grade 2 or below on day 14.
(B) There was also a reduction in the number
of EAE lesions in the lumbar spinal cord in
both treated groups compared to their un-
treated controls, *p  0.04; **p  0.01.
(C) A decrease in the area of the EAE inflam-
matory lesions was also seen in both treated
groups versus their controls, *p  0.01;
**p  0.04.
(D–H) Electron micrographs of lumbar spinal
cord tissue near the site of EAE lesions in
the treated chronic group (D, F–H) and their
untreated control chronic group (E). Note the
large number of degenerating axons in (D)
and (E). Scale bar equals 30 m. The micro-
graphs in (F), (G), and (H) show higher magnifi-
cations of degenerating axons indicated by
arrows in (D). Scale bars equal 5 m.
vated Mycobacterium tuberculosis [Fisher Scientific, Nepean,but not in another (Woelk and Peiler-Ichikawa, 1974;
Canada]). An intravenous injection of 200 ng of pertussis toxin (ListHuterer et al., 1995). Further studies are warranted to
Biologicals, Campbell, CA) was also administered on days 0 and 2assess changes in the expression or activation of PLA2 of the immunization. All procedures were approved by the McGill
enzymes in MS lesions. However, increases of down- University Animal Care committee. The mice were monitored daily
stream products of PLA2 such as prostaglandins and for clinical symptoms of EAE using the following 5-point scale: Grade
0, normal (no clinical signs); Grade 1, flaccid tail; Grade 2, mildleukotrienes have been found in the cerebrospinal fluid
hindlimb weakness (fast righting reflex); Grade 3, severe hindlimbof MS patients (Bolton et al., 1984; Dore-Duffy et al.,
weakness (slow righting reflex); Grade 4, hindlimb paralysis; Grade1986, 1991), and 5-LO, an enzyme downstream of cPLA2
5, hindlimb paralysis and forelimb weakness or moribund.that converts AA to leukotrienes, was recently shown
to be increased in MS and EAE lesions (Whitney et al., Immunohistochemistry
2001). As discussed above, the targets of many of the Mice at different clinical grades were deeply anesthetized and per-
treatments shown to be beneficial in EAE are either fused with 0.1 M phosphate buffer followed by perfusion with 4%
paraformaldehyde in 0.1 M phosphate buffer. Cryostat sections (12chemokines or cytokines that induce expression of
m) of the spinal cord in cross-section were processed using stan-PLA2; or enzymes involved in the conversion of AA to
dard immunoperoxidase methods (Ousman and David, 2000). Theeicosanoids, namely, COX and 5-LO; or molecules in-
primary antibody used was a polyclonal rabbit anti-cPLA2 (Santaduced by LPC, such as ICAM-1 and VCAM-1. Taken Cruz Biotechnology, Santa Cruz, CA, 1:45). The specificity of this
together, these data suggest that PLA2 could serve as antibody was confirmed by Western blot on extracts of NIH 3T3
the common link via which various factors could trigger cells, which showed a single band at 85 kDa. Immunostaining of
tissue sections was lost after pre-adsorption of the polyclonal cPLA2stereotypic cellular changes characteristic of EAE and
antibody with rat glomerular epithelial cells transfected with a cPLA2MS. These studies warrant the designing and testing of
cDNA (obtained from Dr. A. Cybulsky, McGill University). The sec-more potent and specific inhibitors of cPLA2 and further
ondary was a biotinylated goat anti-rabbit antibody (Vector Labora-
their development for the treatment of multiple sclerosis tories, Burlingame, CA, 1:500). Sections were counterstained with
and possibly other neuroinflammatory conditions. 3% methyl green. For double immunofluorescence, cryostat sec-
tions were blocked in 0.1% Triton-X 100 and 2% normal goat serum
and incubated overnight with anti-cPLA2 combined with eitherExperimental Procedures
monoclonal antibodies specific for T cells (rat anti-CD4, BD Biosci-
ences PharMingen, San Diego, CA, 1:100) or macrophages (ratInduction of EAE
EAE was induced in female C57BL/6 mice (18–20 g) by subcutane- monoclonal antibody Mac-1, hybridoma supernatant), followed by
incubation with a biotinylated goat anti-rabbit secondary antibodyous injections of 50 g of myelin oligodendrocyte glycoprotein
(MOG35-55—MEVGWYRSPFSRVVHLYRNGK) (Sheldon Biotechnol- (Jackson ImmunoResearch Laboratories, West Grove, PA, 1:200)
combined with a goat anti-rat rhodamine-conjugated secondary an-ogy Centre, Montreal, Canada) in Complete Freund’s Adjuvant (In-
complete Freund’s adjuvant containing 0.5–1 mg/ml of heat-inacti- tibody (Jackson ImmunoResearch Laboratories, 1:100). After wash-
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ing, the sections were incubated with fluorescein-conjugated strep- housekeeping gene peptidylprolyl isomerase A, which has been
found as a preferred internal control over GAPDH (Feroze-Merzougtavidin (Molecular Probes, Eugene, OR, 1:200).
et al., 2002). Two types of focused gene expression arrays (GEArray)
from SuperArray were used: an array consisting of 67 chemokineQuantification
and chemokine receptor genes (Cat.# MM-005), and a 97 commonCounts were done using an ocular grid. For the immunoperoxidase
cytokine gene array (Cat. #MM-003).stained sections, two types of cPLA2 cells were counted: endothe-
lial cells and immune cells in EAE lesions. Three levels of the spinal
RT-PCRcord (cervical, thoracic, and lumbar) were quantified from 3 animals
RNA was purified from spinal cord as mentioned above. RT-PCRin each grade (grades 1–5). The mean number of each cell type per
was performed using the GeneAmp RNA PCR kit (PerkinElmer Lifecross-section was estimated from three tissue sections per animal,
Sciences). Primers used were as follows: MIP-1, U-5-ATGAAGGTeach section being at least 45 m apart.
CTCCACCACTG-3, L-5-GCATTCAGTTCCAGGTCA-3; IP-10, U-5-For the immunofluorescence stained sections, the number of
CCCCATCAGCACCATGAAC-3, L-5-GCTTCACTCCAGTTAAGGA-3;cPLA2 cells, Mac-1 cells, and CD4 T cells were quantified in 5
Mig, U-5-TGCCATGAAGTCCGCTGTTC-3, L-5-AAAGTAATGGTCrandom lesions in the three levels of the spinal cord from 3 animals
TCTTATGTAG-3; IFN-, U-5-TGAACGCTACACACTGCATCTTGG-in each grade (1–5).
3, L-5-CGACTCCTTTTCCGCTTCCTGAG-3; M-CSF, U-5-AGTMice given delayed treatment and their controls were analyzed
GAG GGA TTT TTG ACC CAG GAA GCA AA-3, L-5-CTA TAC TGGon day 60. Mice were perfused with 4% paraformaldehyde, and
CAG TTC CAC CTG TCT GT-3; and GAPDH, U-5-TGAAGGTCGGTGcryostat cross-sections (12 m) of the spinal cord were stained with
TGAACGGATTTGGC-3, L-5-CATGTAGGCCATGAGGTCCACCAC-hematoxylin and eosin (H&E). Inflammatory lesions were quantified
3. PCR was performed as described previously (Jeong and David,by counting the number of lesions, the number of inflammatory cells,
2003) with annealing temperatures of 60C (MIP-1, M-CSF, andand the area of the infiltrates per section (3 sections per animal and
GAPDH) and 56C (IP-10, Mig, and IFN-).3 animals per group).
All counts were done blind so that the person doing the quantifica-
Electron Microscopytion was unaware of the clinical grade or experimental groups. Re-
On day 60, mice were perfused with 0.5% paraformaldehyde andsults are presented as the mean number of cells per group  stan-
2.5% glutaraldehyde in 0.1 M phosphate buffer. Tissues were thendard error of the mean (SEM). The statistical significance (p  0.05)
postfixed in 2% osmium tetroxide and processed and embeddedbetween the various grades was determined by using a two-sample
in Epon as described previously (Ousman and David, 2000). ThinStudent’s t test.
sections on Collodion-coated slot grids were stained with lead ci-
trate and examined with a Philips CM10 electron microscope.Treatment of EAE
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